ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
16 announcements with these filters
Jagsonpal Pharmaceuticals Ltd will acquire the Wellness Portfolio of Group Pharmaceuticals Ltd. The transaction involves a total consideration capped at ₹46.7 Crore.
Jagsonpal Pharmaceuticals held its 47th Annual General Meeting on September 18, 2026. Shareholders transacted business including adoption of financial statements and director appointments.
Jagsonpal Pharmaceuticals Ltd has filed its Business Responsibility and Sustainability Report for the financial year 2025-26. This report forms part of its annual report.
Jagsonpal Pharmaceuticals Ltd has issued the notice for its 47th Annual General Meeting, scheduled for September 18, 2026, alongside the Annual Report for FY 2025-26.
The company informed shareholders without registered email addresses of the web-link to access the 2025-26 Annual Report and AGM Notice, per Regulation 36(1)(b).
Jagsonpal Pharmaceuticals Limited allotted 27,950 equity shares following the exercise of employee stock options. This increases the company's total paid-up share capital to Rs. 13.19 Crore.
Jagsonpal reported a strong Q1FY27 with 9% revenue growth and 22% PAT growth, outperforming industry rates. The focus is on higher-margin specialty segments and integrating the Equitas acquisition to enter the hospital channel.
Jagsonpal Pharmaceuticals has designated Mr. Balmukund Keshav (DGM-IT) and Mr. Sanjay Singhal (GM-CQA & Regulatory Affairs) as Senior Management Personnel, effective July 29, 2026.
Jagsonpal Pharmaceuticals has granted 1,20,000 employee stock options under its 2022 ESOP plan. The options carry an exercise price of Rs. 179.25 each.
Jagsonpal Pharmaceuticals reported a strong start to FY27 with revenue up 9% YoY and PAT up 22%. The company completed the Aequitas acquisition to enter the hospital supplies segment.
Jagsonpal Pharmaceuticals has scheduled its 47th AGM for September 18, 2026. The company also confirmed September 04, 2026, as the record date for its previously recommended dividend.
Jagsonpal Pharmaceuticals Ltd reported revenue from operations of ₹82.2 Cr (+8.7% YoY) and net profit of ₹13.2 Cr (+22.2% YoY) for Q1 FY27.
Jagsonpal Pharmaceuticals will hold a board meeting on July 29, 2026, to consider and approve its unaudited financial results for the quarter ended June 30, 2026.
Jagsonpal Pharmaceuticals has completed the acquisition of an 85% equity stake in Aequitas Healthcare. This follows initial acquisition intimations made in June 2026.
Jagsonpal Pharmaceuticals allotted 94,000 equity shares under its ESOP scheme. Consequently, the company's paid-up share capital increased to Rs. 13.18 Crore.
Jagsonpal Pharmaceuticals allotted 94,000 equity shares under its 2022 ESOP plan. This exercise increased the paid-up share capital to Rs. 13.19 Crore.